Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): An open-label, phase 3 trial

Cancer

Volumn 118, Issue 24, 2012, Pages 6234-6242

  Sun, Jong Mu ^a   Lee, Ki Hyeong ^b   Kim, Sang We ^c   Lee, Dae Ho ^c   Min, Young Joo ^d   Yun, Hwan Jung ^e   Kim, Hoon Kyo ^f   Song, Hong Suk ^g   Kim, Yeul Hong ^h   Kim, Bong Seog ⁱ   Hwang, In Gyu ^j   Lee, Keehyun ^k   Jo, Sook Jung ^l   Lee, Jae Won ^a,b   Ahn, Jin Seok ^a   Park, Keunchil ^a   Ahn, Myung Ju ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Chungbuk National University Hospital   (South Korea)

^c Asan Medical Center   (South Korea)

^d Ulsan University College of Medicine   (South Korea)

^e Chungnam National University College of Medicine   (South Korea)

^f The Catholic University of Korea   (South Korea)

^g Dongsan Medical Center   (South Korea)

^h Korea University College of Medicine   (South Korea)

ⁱ Seoul Veterans Hospital   (South Korea)

^j Chung Ang University College of Medicine   (South Korea)

^k The Catholic University of Korea   (South Korea)

^l Korea University   (South Korea)

more..

Author keywords

gefitinib; nonsmall cell lung cancer; pemetrexed

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PEMETREXED; PLATINUM COMPLEX;

ACNE; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SOUTH KOREA; THORAX PAIN; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES; QUINAZOLINES; SALVAGE THERAPY; SURVIVAL RATE;

EID: 84870688172     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27630     Document Type: Article

References (18)

1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
2. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-2388.
3. Mitsudomi T, Morita S, Yatabe Y, et al. West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-128.
4. Rosell R, Gervais R, Vergnenegre A, et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. Proc Am Soc Clin Oncol. 2011; 29 (suppl): 476s. Abstract 7503.
5. Zhou CC, Wu YL, Chen GY, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12: 735-742.
6. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008; 372: 1809-1818.
7. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol. 2008; 26: 4244-4252.
8. Lee DH, Park K, Kim JH, et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res. 2010; 16: 1307-1314.
9. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 2006; 24: 3340-3346.
10. Ladanyi M, Pao W,. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008; 21 (suppl 2): S16-S22.
11. Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010; 28: 4616-4620.
12. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 1589-1597.
13. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551.
14. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365-376.
15. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008; 26: 2442-2449.
16. Zhu CQ, da Cunha Santos G, Ding K, et al. National Cancer Institute of Canada Clinical Trials Group Study BR., 21. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008; 26: 4268-4275.
17. Han JY, Park K, Kim SW, et al. First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012; 30: 1122-1128.
18. Salto-Tellez M, Tsao MS, Shih JY, et al. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. J Thorac Oncol. 2011; 6: 1663-1669.